Advertisement

Drug Investigation

, Volume 3, Issue 4, pp 266–269 | Cite as

The Safety and Efficacy of Bufedil® Long (Buflomedil 600mg Delayed Action Tablets) in Patients with Peripheral Arterial Occlusive Disease (Fontaine Stage II a/b)

  • J. Schmidt
Original Research Article

Summary

The symptoms of peripheral arterial occlusive disease (PAOD) can be attributed to tissue hypoxia. Vasoactive drugs such as buflomedil improve microcirculatory blood perfusion despite the presence of large artery occlusions. In this open study, the safety and clinical efficacy of Bufedil® long (buflomedil 600mg delayed action tablets; Abbott Laboratories) were evaluated in 3541 private practice patients with PAOD (Fontaine Stage II a/b). After 8 weeks of therapy, pain-free walking distance increased or doubled for 89.5% of the patients. Claudication pain intensity and the sensation of cold in the lower extremities were reduced in approximately 88% of the patients. Despite the multimorbidity and polypharmacy in this patient population, drug interactions between buflomedil and concurrent medication were not observed. Only 4 patients discontinued the study as a result of adverse events, most of which were mild and transient in nature. Approximately 89% of the patients judged drug compatibility to be good or very good with < 1% reporting poor tolerability.

Keywords

Intermittent Claudication Vasoactive Drug Ischemic Disease Cold Sensation Buflomedil 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bachand RT, Dubourg AY. A review of long-term safety data with buflomedil. Journal of International Medical Research 18: 245–252, 1990PubMedGoogle Scholar
  2. Barker JJ, Menger MD, Sack FU, Messmer K. Nutritive Hautdurchblutung bei partieller Ischamie: Wirkung verschiedener vasoaktiver Substanzen. Vasa 17: 37–41, 1988PubMedGoogle Scholar
  3. Diamantopoulus EJ, Grammoustianos CS, Stavreas NP, Raptis SA, et al. Controlled trial of buflomedil in diabetic peripheral occlusive arterial disease. In Messmer K (Ed.) Ischemic diseases and the microcirculation. New results, pp. 80–84, W. Zuckschwerdt Verlag, Munich, 1989Google Scholar
  4. Diehm C. Begleiterkrankungen und Risikofaktoren bei peripherer arterieller Verschlusskrankheit. In Trubestein G (Hrsg.) Periphere und zentrale Durchblutungsstorungen pp. 28–34, peri med fach buch, Stuttgart, 1988Google Scholar
  5. Diehm C. Pravention der peripheren arteriellen Verschlusskrankheit. In Senn E, Emst E (Hrsg.) Medikamentose und physikalische Therapie der arteriellen Verschlusskrankheit, pp. 71–84, W. Zuckschwerdt Verlag, Munich, 1987Google Scholar
  6. Ehrly AM, Saeger-Lorenz K. Einfluss von Buflomedil i.v. auf den Belastungssauerstoffdruck im Muskelgewebe von Patienten mit Claudication intermittens. Medwelt 40: 1–4, 1989Google Scholar
  7. Fonseca V, Mikhailidis DP, Barradas MA, Jeremy JY, Gracey L, et al. Double-blind placebo-controlled trial of buflomedil in intermittent claudication. International Journal of Clinical Pharmacology Research 8: 377–381, 1988PubMedGoogle Scholar
  8. Forst H, Fujita Y, Racenberg J, Bruckner U, Weiss T, et al. Skelettmuskeldurchblutung bei arterieller Verschlusskrankheit; wirkung verschiedener Therapieverfahren. In Hammersen F, Messmer K (Hrsg.) Die Mikrozirkulation des Skelettmuskels, pp. 119–135, Karger Verlag, Basle, 1984Google Scholar
  9. Gottstein P. Additive Wirkung von Buflomedil bei gleichzeitigem Training. Zeitschrift für Allgemeinmedizin 63: 836–839, 1987Google Scholar
  10. Grus JD. Operative Therapie im fortgeschrittenen Stadium der AVK (Stadium III und IV). In Trubestein G (Hrsg.) Therapie der arteriellen Verschlusskrankheit, pp. 74–79, W. Zuckschwerdt Verlag, Munich, 1986Google Scholar
  11. Heidrich H. Periphere arterielle Verschlusskrankheit. Therapiewoche 39: 1721–1724, 1989aGoogle Scholar
  12. Heidrich H. Rationelles Therapiekonzept 1989 in der Behandlung peripherer arterieller Durchblutungsstorungen. Therapiewoche 39: 1809, 1989bGoogle Scholar
  13. Intaglietta M. Vasomotion: physiology and pathology. In Messmer K (Ed.) Ischemic diseases and the microcirculation. New results, pp. 38–43, W. Zuckschwerdt Verlag, Munich, 1989Google Scholar
  14. Lewis DH. Microcirculation and rheology: an introduction. In Messmer K (Ed.) Ischemic diseases and the microcirculation. New results, pp. 1–5, W. Zuckschwerdt Verlag, Munich, 1989Google Scholar
  15. Lowe GDO, Andersen J, Lockhart J. Red cell aggregation and deformation in ischemia: effects of buflomedil in vitro. In Messmer K (Ed.) Ischemic diseases and the microcirculation. New results, pp. 6–11, W. Zuckschwerdt Verlag, Munich, 1989Google Scholar
  16. Marshall M. Epidemiologie der arteriellen Verschluskrankheit. In Kluken N (Hrsg.) Diagnose und Therapie der arteriellen Verschlusskrankheit, Vol. 33, pp. 1–14, 1986Google Scholar
  17. Racenberg J, Intaglietta M, Messmer K. Die Wirkungen des vasoaktiven Medikamentes Buflomedil bei der arteriellen Verschlusskrankheit. Fortschritte der Medizin 41: 1926–1930, 1982Google Scholar
  18. Ranft J. Stellenwert moderner Mikrozirkulationsuntersuchungen. Therapiewoche 39: 1746–1756, 1989Google Scholar
  19. Rose GA. The diagnosis of ischemic heart pain and intermittent claudication in field surveys. Bulletin of the World Health Organization 27: 645, 1962PubMedGoogle Scholar
  20. Sack FU, Zeintl H, Galla TJ, Messmer K. Dynamics of leucocyte adhesion to the microvascular endotheium in response to ischemia: effect of buflomedil. In Messmer K (Ed.) Ischemic diseases and the microcirculation. New results, pp. 22–30, W. Zuckschwerdt Verlag, Munich, 1989Google Scholar
  21. Sunder-Plassmann L. Bedeutung des Kollateralwiderstandes bei arterieller Verschlusskrankheit. Therapiewoche 33: 93–100, 1983Google Scholar
  22. Trubestein G, Balzer K, Bisler H, Kluken N, Mahfoud Y, et al. Buflomedil bei arterieller Verschlusskrankheit. In Trubestein G (Hrsg.) Konservative Therapie arterieller Durchblutungsstorungen, pp. 75–81, Thieme Verlag, Stuttgart, 1986Google Scholar

Copyright information

© Adis International Limited 1991

Authors and Affiliations

  • J. Schmidt
    • 1
  1. 1.Deutsche Abbott GmbHWiesbadenGermany

Personalised recommendations